Have any questions?
+1-862-686-3898
CAS No.: 313967-18-9
Inquire FLI-06 (cas: 313967-18-9 ) online by filling out the inquiry form, we will get back to you within 24 hours!
Product Details | |
---|---|
For research use only. Not Intended for Therapeutic Use! |
|
Cat No: | I003113 |
Synonyms: | cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,6,8-tetrahydroquinoline-3-carboxylate |
Molecular Formula: | C₂₅H₃₀N₂O₅ |
Molecular Weight: | 438.52 |
IC50:: | 2.3 uM (EC50) [1] |
Description: | FLI-06 is a novel potent and selective small molecule intercepting Notch signaling and the early secretory pathway (EC50 ~2.3 μM), identified by using automated microscopy to monitor the trafficking and processing of a ligand-independent Notch-GFP fusion reporter.IC50 value: 2. |
Price: | Get quote |
We would like to match the lowest price on market if possible.
FLI-06 is a novel potent and selective small molecule intercepting Notch signaling and the early secretory pathway (EC50 ~2.3 μM), identified by using automated microscopy to monitor the trafficking and processing of a ligand-independent Notch-GFP fusion reporter.
IC50 value: 2.3 uM (EC50) [1]
Target: Notch signaling
FLI-06 can induce accumulation of the reporter at the plasma membrane by interfering with transport in the secretory pathway. It can also disrupt the Golgi apparatus in a manner distinct from that of brefeldin A and golgicide A. FLI-06 inhibited general secretion at a step before exit from the endoplasmic reticulum (ER), which was accompanied by a tubule-to-sheet morphological transition of the ER, rendering FLI-06 the first small molecule acting at such an early stage in secretory traffic. FLI-06 is a very useful chemical probe to study the inhibition of membrane traffic at pre- ER-exit site (ERES) stages without fusion of ER-Golgi.
Your information is safe with us.